Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06237049 · ClinicalTrials.gov registry record · Phase 2
A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 644
- Enrollment target
NCT06237049: Completed Phase 2 study, sponsored by Pfizer.
NCT06237049 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 644 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (384% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06237049, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 644 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to see if combining a licensed COVID-19 vaccine and a licensed influenza vaccine into a single shot is safe and can help produce antibodies to defend the body against both SARS-CoV-2 (the virus that causes COVID-19) and influenza. Participants enrolled in this trial will be healthy adults, 50 years of age or older.
Primary Outcome
Local reactions included redness, swelling and pain at injection site, recorded by participants in an electronic diary (e-diary). Severity of all local reactions were evaluated as mild, moderate, severe or potentially life-threatening. In this outcome measure local reactions with any severity were reported for each left arm's deltoid and right arm's deltoid of each vaccine Group 1, 2, 3 and 4.
Interventions
- BIOLOGICAL BNT162b2 (Omi XBB.1.5)
- BIOLOGICAL BNT162b2 (Omi XBB.1.5)/RIV
- BIOLOGICAL RIV
- OTHER Normal saline placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 644 participants |
| Start Date | 2024-01-31 |
| Est. Completion | 2024-09-13 |
| Phase | Phase 2 |
What the finished NCT06237049 record still lists
NCT06237049 is an interventional study that assigns participants to a tested intervention. The registered 644 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (384% higher).
The record links to 0 conditions, and to 4 interventions - of which BNT162b2 (Omi XBB.1.5) is the first listed.
NCT06237049 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06237049 about?
NCT06237049 is a clinical study titled "A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults". The purpose of this clinical trial is to see if combining a licensed COVID-19 vaccine and a licensed influenza vaccine into a single shot is safe and can help produce antibodies to defend the body against both SARS-CoV-2 (the virus that causes COVID-19) and influenza. Participants enrolled in this t...
What is the current status of trial NCT06237049?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 644 participants. The study started on 2024-01-31. Estimated completion is 2024-09-13.
What interventions are being tested in trial NCT06237049?
The interventions under investigation include: BNT162b2 (Omi XBB.1.5) (BIOLOGICAL), BNT162b2 (Omi XBB.1.5)/RIV (BIOLOGICAL), RIV (BIOLOGICAL), Normal saline placebo (OTHER).
Who is sponsoring clinical trial NCT06237049?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06237049's enrollment target sits among peer trials
644 50th of 2000 higher than 1,951 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05146297 · 644 participants · NA
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
- NCT06994442 · 644 participants · Phase 3
Optimizing Pain Treatment in Children On Mechanical Ventilation
- NCT07012395 · 645 participants · Phase 2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- NCT04863222 · 646 participants · Phase 4
Clinical and Radiographic Success of MTA vs Biodentine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI